Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 226 of 6351
-
Breakthrough? stool test may spot Alzheimer's before symptoms worsen
Diagnosis Recruiting nowAlzheimer's disease (AD) is the leading cause of dementia in humans, currently affecting almost one million people in France. It results from an irreversible degeneration of neurons responsible for a progressive decline in the main cognitive and memory functions due to a cerebral…
Sponsor: University Hospital, Grenoble • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New hope for early breast cancer: targeted therapy may replace chemo
Disease control Recruiting nowTNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour size \>5 mm according to current National Comprehensiv…
Phase 3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Lung cancer combo therapy aims to shrink tumors before surgery
Disease control Recruiting nowThis is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to be surgic…
Phase 1/2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a single psychedelic dose rewire the depressed brain?
Disease control OngoingThis study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted p…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Weekly HIV pill could replace daily doses
Disease control OngoingThe goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard of care treatment in people with human immunodeficiency virus (PWH) who are virologically sup…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to outperform standard lung cancer therapy
Disease control Recruiting nowThe purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Which pill works best for bipolar depression? huge study aims to find out
Disease control OngoingThis is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 and type 2 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar …
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New trial aims to match AML patients with best drug combo
Disease control Recruiting nowAcute myeloid leukemia (AML) is a common hematological malignancy. Intensive chemotherapy is the main treatment in fit patients. Retrospective studies have shown that Venetoclax is highly effective in elder AML patients with IDH2 and NPM1 mutations while in those with TP53 and F…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Hope for Alzheimer's psychosis: new drug KarXT enters final trial
Symptom relief Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a triple-drug combo outsmart stubborn ovarian cancer?
Disease control Recruiting nowDisitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Bionic pancreas could simplify diabetes care for cystic fibrosis patients
Disease control Recruiting nowThis multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a new antibody calm stubborn eczema when steroids fall short?
Disease control CompletedThis is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic derma…
Phase 3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New trial aims to boost survival in kidney cancer by combining radiation with drug therapy
Disease control Recruiting nowThis phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma. The study aims to determine if the addition of SBRT to standard systemic therapy prolong survival compared to the standard syst…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug duo takes on tough melanoma before surgery
Disease control OngoingThis study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of …
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a B-Cell blocker tame lupus?
Disease control OngoingThis study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for Drug-Resistant lung cancer: experimental pill enters human trials
Disease control Recruiting nowThe goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant sel…
Phase 1/2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a simpler antibiotic course clear lung infections as well as a stronger one?
Disease control Recruiting nowChronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis. Current guidelines suggest the prescription of an eradication antibi…
Phase 2 • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo aims to spare surgery for certain cancer patients
Disease control Recruiting nowThis study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability
Phase 2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can community conversations curb suicide in rural alaska?
Disease control OngoingThis participatory, pragmatic efficacy-implementation trial evaluates the impact of Promoting Community Conversations About Research to End Suicide (PC CARES) to evaluate Learning Circle (LC) participant outcomes (AIM#1), community-wide diffusion effects, and efficacy by tracking…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC